Xontogeny CEO Chris Garabedian unveiled two rounds of Series A financing on Tuesday: one for Tellus Therapeutics, a neonatal care company, and another for Peroxitech, a biopharma working on a peptide for treating acute lung injury.
Tellus Therapeutics Announces $35 Million Series A Financing